November 2024's Top Penny Stocks To Consider

As global markets show broad-based gains, with U.S. indexes nearing record highs and smaller-cap indexes outperforming, investors are increasingly looking for opportunities in less traditional areas of the market. Penny stocks, though an outdated term, continue to offer intriguing possibilities for those seeking growth at lower price points. These stocks often represent smaller or newer companies that can provide significant returns when backed by strong financials and solid fundamentals.

Top 10 Penny Stocks

Name	Share Price	Market Cap	Financial Health Rating
DXN Holdings Bhd (KLSE:DXN)	MYR0.48	MYR2.39B	★★★★★★
Embark Early Education (ASX:EVO)	A$0.80	A$146.79M	★★★★☆☆
Lever Style (SEHK:1346)	HK$0.86	HK$545.92M	★★★★★★
LaserBond (ASX:LBL)	A$0.565	A$66.23M	★★★★★★
Hil Industries Berhad (KLSE:HIL)	MYR0.89	MYR295.43M	★★★★★★
ME Group International (LSE:MEGP)	£2.22	£836.42M	★★★★★★
Next 15 Group (AIM:NFG)	£4.20	£417.71M	★★★★☆☆
Secure Trust Bank (LSE:STB)	£3.92	£74.76M	★★★★☆☆
United U-LI Corporation Berhad (KLSE:ULICORP)	MYR1.55	MYR337.59M	★★★★★★
SHAPE Australia (ASX:SHA)	A$2.79	A$231.32M	★★★★★★

Click here to see the full list of 5,755 stocks from our Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Nightingale Health Oyj (HLSE:HEALTH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nightingale Health Oyj is a health technology company that provides a health data platform for detecting disease risks across Finland, the United Kingdom, Europe, the United States, and internationally, with a market cap of €182.23 million.

Operations: The company generates revenue from its Medical Labs & Research segment, amounting to €4.36 million.

Market Cap: €182.23M

Nightingale Health Oyj, with a market cap of €182.23 million, is navigating the penny stock landscape with strategic moves such as its partnership with Boston Heart Diagnostics to expand its Health Check service in the U.S. Despite generating €4.36 million in revenue from its Medical Labs & Research segment, it remains unprofitable and is not expected to achieve profitability in the near term. The company has a solid cash runway exceeding three years and minimal debt, positioning it well for future growth opportunities. Recent executive appointments aim to bolster its strategic direction and global reach in health technology.

• Click here to discover the nuances of Nightingale Health Oyj with our detailed analytical financial health report.
• Evaluate Nightingale Health Oyj's prospects by accessing our earnings growth report.

Golden Solar New Energy Technology Holdings (SEHK:1121)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Golden Solar New Energy Technology Holdings Limited is an investment holding company that manufactures and sells footwear products across various international markets including the People’s Republic of China, the United States, South America, Europe, and South East Asia with a market cap of approximately HK$4.10 billion.

Operations: The company generates revenue from several segments, including CN¥1.72 million from Boree Products, CN¥49.29 million from Photovoltaic Products, CN¥7.01 million from Graphene-Based Products, and CN¥209.30 million through its Original Equipment Manufacturer (OEM) operations.

Market Cap: HK$4.1B

Golden Solar New Energy Technology Holdings, with a market cap of approximately HK$4.10 billion, operates in diverse markets but remains unprofitable. The company reported sales of CN¥127.48 million for the first half of 2024, down from CN¥155.52 million the previous year, with net losses widening to CN¥158.18 million. Despite its experienced management and board, Golden Solar faces financial challenges including a negative return on equity and less than one year of cash runway. Recent share buybacks totaling 1,810,000 shares may indicate efforts to stabilize shareholder value amidst high share price volatility.

• Take a closer look at Golden Solar New Energy Technology Holdings' potential here in our financial health report.
• Assess Golden Solar New Energy Technology Holdings' previous results with our detailed historical performance reports.

Zhejiang Reclaim Construction Group (SZSE:002586)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Zhejiang Reclaim Construction Group Co., Ltd. operates in the construction industry and has a market cap of CN¥2.40 billion.

Operations: The company's revenue is derived entirely from its operations in China, amounting to CN¥2.23 billion.

Market Cap: CN¥2.4B

Zhejiang Reclaim Construction Group, with a market cap of CN¥2.40 billion, operates solely in China and reported sales of CN¥1.36 billion for the first nine months of 2024, up from CN¥1.26 billion the previous year. Despite this revenue growth, the company remains unprofitable with a net loss of CN¥83.05 million, though losses have decreased over five years at an annual rate of 38.1%. It has reduced its debt to equity ratio significantly over five years and holds more cash than total debt, providing a stable cash runway for more than one year without shareholder dilution recently.

• Navigate through the intricacies of Zhejiang Reclaim Construction Group with our comprehensive balance sheet health report here.
• Examine Zhejiang Reclaim Construction Group's past performance report to understand how it has performed in prior years.

Seize The Opportunity

• Get an in-depth perspective on all 5,755 Penny Stocks by using our screener here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com